Case report: Optimized ruxolitinib-based therapy in an infant with familial hemophagocytic lymphohistiocytosis type 3
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Case report: Optimized ruxolitinib-based therapy in an infant with familial hemophagocytic lymphohistiocytosis type 3
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-11-23
DOI
10.3389/fimmu.2022.977463
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A study of Ruxolitinib-response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis
- (2022) Qing Zhang et al. BLOOD
- The role of JAK inhibitors in hematopoietic cell transplantation
- (2022) Rachel B. Salit BONE MARROW TRANSPLANTATION
- Familial hemophagocytic lymphohistiocytosis hepatitis is mediated by IFN-γ in a predominantly hepatic-intrinsic manner
- (2022) Tamir Diamond et al. PLoS One
- Recurrent tandem duplication of UNC13D in familial hemophagocytic lymphohistiocytosis type 3
- (2022) Dan Tomomasa et al. CLINICAL IMMUNOLOGY
- Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide in Pediatric Hemophagocytic Lymphohistiocytosis
- (2021) Diego Medina-Valencia et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Successful management of familial hemophagocytic lymphohistiocytosis by the JAK 1/2 inhibitor ruxolitinib
- (2021) Louis Marois et al. PEDIATRIC BLOOD & CANCER
- Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective
- (2021) Michael P. Triebwasser et al. PEDIATRIC BLOOD & CANCER
- Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome
- (2021) Eduardo Huarte et al. Frontiers in Pharmacology
- Successful rescue of a lethal Griscelli syndrome type 2 presenting with neurological involvement and hemophagocytic lymphohistiocytosis: a case report
- (2021) Qing Zhang et al. BMC Pediatrics
- Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
- (2021) Robert Zeiser et al. NEW ENGLAND JOURNAL OF MEDICINE
- IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS
- (2021) Howard Lin et al. Blood Advances
- Successful ruxolitinib administration for a patient with steroid‐refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review
- (2021) Dan Tomomasa et al. Clinical Case Reports
- Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
- (2020) Yang Cao et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
- (2020) Robert Zeiser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis
- (2020) Franco Locatelli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children
- (2020) Ang Wei et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Clinical, Immunological and Genetic findings in Patients with UNC13D Deficiency (FHL3): a Systematic Review
- (2020) Parisa Amirifar et al. PEDIATRIC ALLERGY AND IMMUNOLOGY
- Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis
- (2020) Matthias Felber et al. Blood Advances
- Frequency and spectrum of disease-causing variants in 1892 patients with suspected genetic HLH disorders
- (2020) Vanessa Gadoury-Levesque et al. Blood Advances
- A Cry for the Development of Newborn Screening for Familial Hemophagocytic Lymphohistiocytosis
- (2020) Akihiro Hoshino et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Cytokine Storm
- (2020) David C. Fajgenbaum et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Action of Ruxolitinib in Murine Models of Hemophagocytic Lymphohistiocytosis
- (2019) Sabrin Albeituni et al. BLOOD
- Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic stem cell transplantation for refractory hemophagocytic lymphohistiocytosis
- (2019) Yanmin Zhao et al. BONE MARROW TRANSPLANTATION
- Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis
- (2019) Jingshi Wang et al. HAEMATOLOGICA
- Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
- (2019) Maiko Takakura et al. CLINICAL IMMUNOLOGY
- Successful remission induction in refractory familial hemophagocytic lymphohistiocytosis with ruxolitinib as a bridge to hematopoietic stem cell transplantation
- (2019) Kesavan Melarcode Ramanan et al. PEDIATRIC BLOOD & CANCER
- Characterization of a large UNC13D gene duplication in a patient with familial hemophagocytic lymphohistiocytosis type 3
- (2018) Eitaro Hiejima et al. CLINICAL IMMUNOLOGY
- Successful Haploidentical Stem Cell Transplant With Posttransplant Cyclophosphamide for Hemophagocytic Lymphohistiocytosis
- (2018) Shruti Kohli et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group
- (2013) Daisuke Tomizawa et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Cytokine profiles in children with primary Epstein-Barr virus infection
- (2013) Taizo Wada et al. PEDIATRIC BLOOD & CANCER
- JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
- (2012) John J. O'Shea et al. IMMUNITY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab
- (2012) Rebecca A. Marsh et al. PEDIATRIC BLOOD & CANCER
- CXCR3 ligands: redundant, collaborative and antagonistic functions
- (2011) Joanna R Groom et al. IMMUNOLOGY AND CELL BIOLOGY
- The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
- (2011) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3
- (2011) E. Sieni et al. JOURNAL OF MEDICAL GENETICS
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started